[{"address1": "80 Guest Street", "address2": "Suite 601", "city": "Boston", "state": "MA", "zip": "02135", "country": "United States", "phone": "617 500 8099", "website": "https://www.compasstherapeutics.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in the development of antibody-based therapeutics for the treatment of various human diseases in the United States. The company's lead product candidates include tovecimig, a bispecific antibody that blocks Delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF-A) signaling pathways, which are critical to angiogenesis and tumor vascularization; CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells; and CTX-8371, a bispecific inhibitor that targets programmed cell death protein-1 (PD-1) and ligand PD-L1 checkpoint inhibitor antibodies. It also develops CTX-10726, a bispecific antibody that targets PD-1 and VEFG-A; and VEGF-IO Bispecific / Multiple, a bispecific antibody engages the angiogenesis pathway and anti-tumor immune that targets, including immune checkpoints, as well as analyzes VEGF combinations with other immune response-related proteins. Compass Therapeutics, Inc. was founded in 2014 and is headquartered in Boston, Massachusetts.", "fullTimeEmployees": 35, "companyOfficers": [{"maxAge": 1, "name": "Dr. Thomas J. Schuetz M.D., Ph.D.", "age": 63, "title": "CEO & Vice Chairman", "yearBorn": 1961, "fiscalYear": 2024, "totalPay": 994800, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Barry  Shin J.D., M.B.A.", "age": 52, "title": "Chief Financial Officer", "yearBorn": 1972, "fiscalYear": 2024, "totalPay": 406256, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Jonathan E. Anderman J.D.", "title": "Senior VP, General Counsel & Corporate Secretary", "fiscalYear": 2024, "totalPay": 541620, "exercisedValue": 0, "unexercisedValue": 6250}, {"maxAge": 1, "name": "Ms. Vered  Bisker-Leib MBA, Ph.D.", "age": 53, "title": "Advisor", "yearBorn": 1971, "fiscalYear": 2024, "totalPay": 1531657, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Neil L. Lerner CPA", "age": 57, "title": "Senior VP & Chief Accounting Officer", "yearBorn": 1967, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Anna  Gifford", "title": "Communications Manager", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Minori  Rosales M.D., Ph.D.", "age": 61, "title": "Senior VP & Head of Clinical Development", "yearBorn": 1963, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Karin  Herrera B.A.", "title": "Senior VP & Head of Clinical Operations", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. James  Kranz Ph.D.", "title": "VP and Head of Chemistry Manufacturing & Controls", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 7, "boardRisk": 7, "compensationRisk": 9, "shareHolderRightsRisk": 8, "overallRisk": 8, "governanceEpochDate": 1754006400, "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 4, "previousClose": 2.78, "open": 2.79, "dayLow": 2.671, "dayHigh": 2.805, "regularMarketPreviousClose": 2.78, "regularMarketOpen": 2.79, "regularMarketDayLow": 2.671, "regularMarketDayHigh": 2.805, "payoutRatio": 0.0, "beta": 1.296, "forwardPE": -5.294118, "volume": 563868, "regularMarketVolume": 563868, "averageVolume": 815665, "averageVolume10days": 740640, "averageDailyVolume10Day": 740640, "bid": 2.67, "ask": 2.73, "bidSize": 2, "askSize": 4, "marketCap": 383734816, "fiftyTwoWeekLow": 1.12, "fiftyTwoWeekHigh": 4.08, "priceToSalesTrailing12Months": 451.45273, "fiftyDayAverage": 2.6856, "twoHundredDayAverage": 2.243175, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 267108752, "profitMargins": 0.0, "floatShares": 88910115, "sharesOutstanding": 138282000, "sharesShort": 7842888, "sharesShortPriorMonth": 7389202, "sharesShortPreviousMonthDate": 1749772800, "dateShortInterest": 1752537600, "sharesPercentSharesOut": 0.056700002, "heldPercentInsiders": 0.14163, "heldPercentInstitutions": 0.67879, "shortRatio": 9.15, "shortPercentOfFloat": 0.1075, "impliedSharesOutstanding": 142124000, "bookValue": 0.797, "priceToBook": 3.387704, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1743379200, "netIncomeToCommon": -55221000, "trailingEps": -0.39, "forwardEps": -0.51, "enterpriseToRevenue": 314.246, "enterpriseToEbitda": -4.361, "52WeekChange": 1.460177, "SandP52WeekChange": 0.19554341, "quoteType": "EQUITY", "currentPrice": 2.7, "targetHighPrice": 32.0, "targetLowPrice": 6.0, "targetMeanPrice": 12.8, "targetMedianPrice": 9.5, "recommendationMean": 1.3, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 10, "totalCash": 112635000, "totalCashPerShare": 0.815, "ebitda": -61246000, "totalDebt": 6381000, "quickRatio": 7.559, "currentRatio": 8.332, "totalRevenue": 850000, "debtToEquity": 5.786, "revenuePerShare": 0.006, "returnOnAssets": -0.26411, "returnOnEquity": -0.41312, "grossProfits": 850000, "freeCashflow": -25007124, "operatingCashflow": -44175000, "grossMargins": 1.0, "ebitdaMargins": 0.0, "operatingMargins": -72.73059, "financialCurrency": "USD", "symbol": "CMPX", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Delayed Quote", "triggerable": true, "customPriceAlertConfidence": "HIGH", "shortName": "Compass Therapeutics, Inc.", "longName": "Compass Therapeutics, Inc.", "corporateActions": [], "marketState": "CLOSED", "postMarketTime": 1754694213, "regularMarketTime": 1754683201, "exchange": "NCM", "messageBoardId": "finmb_266166780", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "regularMarketChangePercent": -2.8777, "regularMarketPrice": 2.7, "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1617629400000, "postMarketChangePercent": 0.37037, "postMarketPrice": 2.71, "postMarketChange": 0.00999999, "regularMarketChange": -0.0799999, "regularMarketDayRange": "2.671 - 2.805", "fullExchangeName": "NasdaqCM", "averageDailyVolume3Month": 815665, "fiftyTwoWeekLowChange": 1.58, "fiftyTwoWeekLowChangePercent": 1.4107143, "fiftyTwoWeekRange": "1.12 - 4.08", "fiftyTwoWeekHighChange": -1.3799999, "fiftyTwoWeekHighChangePercent": -0.33823526, "fiftyTwoWeekChangePercent": 146.0177, "earningsTimestamp": 1754884800, "earningsTimestampStart": 1754884800, "earningsTimestampEnd": 1754884800, "isEarningsDateEstimate": false, "epsTrailingTwelveMonths": -0.39, "epsForward": -0.51, "epsCurrentYear": -0.48571, "priceEpsCurrentYear": -5.5588727, "fiftyDayAverageChange": 0.014400005, "fiftyDayAverageChangePercent": 0.0053619323, "twoHundredDayAverageChange": 0.45682502, "twoHundredDayAverageChangePercent": 0.20365109, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "ipoExpectedDate": "2021-11-02", "averageAnalystRating": "1.3 - Strong Buy", "cryptoTradeable": false, "displayName": "Compass Therapeutics", "trailingPegRatio": null, "__fetch_time": "2025-08-09"}]